Close

Natera Announces Real-World Data Collaboration with Merck

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Evolution of Regulatory Frameworks for Real-World Data

The pharmaceutical landscape has undergone a profound transformation as...

Biomarker Discovery Digital Age Standardization Validation

The biomarker discovery digital standardization landscape represents one of...

The Way Forward for the Healthcare Data Ecosystem

The transformation of worldwide healthcare by way of digital...

Real-World Data in Managing Pharmaceutical Efficacy-Effectiveness Gap

The pharmaceutical sector stands at a very critical crossroads...

Natera, Inc., a global leader in cell-free DNA testing announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, under which Merck will utilize Natera’s real-world database (RWD) to advance oncology research.

Natera’s oncology RWD contains de-identified clinical and genomic data from more than 100,000 early- and late-stage patients with cancer who have been tested with Signatera™, the company’s personalized and tumor-informed molecular residual disease (MRD) test. Longitudinal monitoring data is available for the majority of patients, providing an objective measure of molecular response to treatment and connected to a multi-modal database that includes clinical outcomes, genomic profiling, and imaging. Pharmaceutical companies can use Natera’s RWD to strategically advance drug development programs across early-stage and metastatic settings.

“With Signatera being ordered now on a regular basis by over a third of all oncologists in the U.S., Natera is in a unique position to structure and share its real-world experience to inform drug discovery and clinical research,” said John Fesko, Natera’s president & chief business officer.

Latest stories

Related stories

Evolution of Regulatory Frameworks for Real-World Data

The pharmaceutical landscape has undergone a profound transformation as...

Biomarker Discovery Digital Age Standardization Validation

The biomarker discovery digital standardization landscape represents one of...

The Way Forward for the Healthcare Data Ecosystem

The transformation of worldwide healthcare by way of digital...

Real-World Data in Managing Pharmaceutical Efficacy-Effectiveness Gap

The pharmaceutical sector stands at a very critical crossroads...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back